Claim 55% Off TipRanks
Trade SRPT with leverageSarepta Therapeutics ( (SRPT) ) has issued an announcement.
On February 25, 2026, Sarepta Therapeutics said Chief Executive Officer Douglas Ingram notified the company of his decision to retire by the end of 2026 or when a successor is appointed. The board has begun searching both internal and external candidates, signaling a planned leadership transition that may shape Sarepta’s strategic direction and execution over the coming years.
The most recent analyst rating on (SRPT) stock is a Hold with a $17.00 price target. To see the full list of analyst forecasts on Sarepta Therapeutics stock, see the SRPT Stock Forecast page.
Spark’s Take on SRPT Stock
According to Spark, TipRanks’ AI Analyst, SRPT is a Neutral.
Sarepta Therapeutics’ overall stock score reflects significant financial challenges, particularly in profitability and cash flow, despite some positive technical indicators and strategic debt management. The company’s valuation remains a concern due to negative earnings, and while recent earnings call and corporate events provide some optimism, they are not enough to offset the financial weaknesses.
To see Spark’s full report on SRPT stock, click here.
More about Sarepta Therapeutics
Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on developing precision genetic medicines, including therapies for rare neuromuscular diseases. The company operates in the biotechnology sector, targeting serious and life-threatening conditions with high unmet medical need.
Average Trading Volume: 2,787,997
Technical Sentiment Signal: Sell
Current Market Cap: $1.97B
For detailed information about SRPT stock, go to TipRanks’ Stock Analysis page.